Skip to content
Back to Publications

Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: an AI-based analysis from the SYMMETRY randomized controlled trial

Conference

AASLD

Partner

Akero Therapeutics

Authors

  • Gachechiladze et al.